Kuros Biosciences Swings to Profit in H1; Revenue Up

01:23 AM EDT, 08/13/2026 (MT Newswires) -- Kuros Biosciences (KURN.SW) said Thursday it swung to a net profit in the first half, while revenue rose year over year. Net profit for the six months ended June 30 was $4.4 million, compared with a loss of $2 million a year earlier. EPS was $0.11, compared with a loss per share of $0.05. The biopharmaceutical company's revenue from product sales was $92.4 million, compared with $63.5 million a year ago. Looking ahead, the company confirmed its sales growth outlook of at least 35% in 2026, and affirmed its expectation for 2028 sales of between $300 million and $330 million.